Modulation of multiple pathways involved in the maintenance of neuronal function by fisetin

Micronutrients and Brain Health

Volumn , Issue , 2009, Pages 189-206

  Maher, Pamela ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057672854     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (114)

1. Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatiit, V., Recanatini, M., and Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem. 2008, 51, 347-372.
2. Hellerstein, M. K. A critique of the molecular target-based drug discovery paradigm based on principles of metabolic control: Advantages of pathway-based discovery. Met. Engineer 2008, 10, 1-9.
3. Pangalos, M. N., Schechter, L. E., and Hurko, O. Drug development for CNS disorders: Strategies for balancing risk and reducing attrition. Nature Rev. Drug Discov. 2007, 6, 521-532.
4. Middleton, E., Kandaswami, C., and Theoharides, T. C. The effects of flavonoids on mammalian cells:Implications for inflammation, heart disease and cancer. Pharmacol. Rev. 2000, 52, 673-751.
5. Heim, K. E., Tagliaferro, A. R., and Bobilya, D. J. Flavonoid antioxidants: Chemistry, metabolism and structure-activity relationships. J. Nutr. Biochem. 2002, 13, 572-584.
6. Ross, J. A., and Kasum, C. M. Dietary flavonoids: Bioavailability, metabolic effects, and safety. Annu. Rev. Nutr. 2002, 22, 19-34.
7. Tan, S., Schubert, D., Maher, and P. Oxytosis: A novel form of programmed cell death. Curr. Top. Med. Chem. 2001, 1, 497-506.
8. Ishige, K., Schubert, D., and Sagara, Y. Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. Free Radic. Biol. Med. 2001, 30, 433-446.
9. Ingall, T. Stroke - Incidence, mortality and risk. J. Insur. Med. 2004, 36, 143-152.
10. Lapchak, P. A., and Araujo, D. M. Advances in ischemic stroke treatment: Neuroprotective and combination therapies. Expert Opin. Emerg. Drugs 2007, 12, 97-112.
11. Green, A. R., and Shuaib, A. Therapeutic strategies for the treatment of stroke. Drug Disc. Today 2006, 11, 681-693.
12. Lyden, P. D., and Zivin, J. A. Hemorrhagic transformation after cerebral ischemia: Mechanisms and incidence. Cerebrovasc. Brain Metab. Rev. 1993, 5, 1-16.
13. Lapchak, P. A. Development of thrombolytic therapy for stroke: A perspective. Expert Opin. Investig. Drugs 2002, 11, 1623-1632.
14. Lapchak, P. A. Hemorrhagic transformation following ischemic stroke: Significance, causes and relationship to therapy and treatment. Curr. Neurol. Neurosci. Rep. 2002, 2, 38-43.
15. Maher, P., Salgado, K. F., Zivin, J. A., and Lapchak, P. A. A novel approach to screening for new neuroprotective compounds for the treatment of stroke. Brain Res. 2007, 1173, 117-125.
16. Rivera, F., Urbanavicius, J., Gervaz, E., Morquio, A., and Dajas, F. Some aspects of the in vivo neuroprotective capacity of flavonoids: Bioavailability and structure-activity relationship. Neurotox. Res. 2004, 6, 543-553.
17. Singh, I. N., Sullivan, P. G., Deng, Y., Mbye, L. H., and Hall, E. D. Time course of post-traumatic mitochondrial oxidative damage and dysfunction in a mouse model of focal traumatic brain injury:Implications for neuroprotective therapy. J. Cereb. Blood Flow Metab. 2006, 26, 1407-1418.
18. Xiong, Y. and Hall, E. D. Pharmacological evidence for a role of peroxynitrite in the pathophysiology of spinal cord injury. Exp. Neurol. 2009, 216, 105-114.
19. Eliasson, M. J. L., Huang, Z., Ferrante, R. J., Sasamata, M., Molliver, M. E., Snyder, S. H., and Moskowitz, M. A. Neuronal nitric oxide synthase activation and peroxynitrite formation in ischemic stroke linked to neuronal damage. J. Neurosci. 1999, 19, 5910-5918.
20. Torreilles, F., Salman-Tabcheh, S., Guerin, M., and Torreilles, J. Neurodegenerative disorders: The role of peroxynitrite. Brain Res. Brain Res. Rev. 1999, 30, 153-163.
21. Beckman, J. S., Beckman, T. W., Chen, J., Marshall, P. A., and Freeman, B. A. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. U S A 1990, 87, 1620-1624.
22. Beckman, J. S., Ischiropoulos, H., Zhu, L., van der Woerd, M., Smith, C., Chen, J., Harrison, J., Martin, J. C., and Tsai, M. Kinetics of superoxide dismutase- and iron-catalyzed nitration of phenolics by peroxynitrite. Arch. Biochem. Biophys. 1992, 298, 438-445.
23. Ischiropoulos, H., Zhu, L., Chen, J., Tsai, M., Martin, J. C., Smith, C. D., and Beckman, J. S. Peroxynitritemediated tyrosine nitration catalyzed by superoxide dismutase. Arch. Biochem. Biophys. 1992, 298, 431-437.
24. Radi, R., Beckman, J. S., Bush, K. M., and Freeman, B. A. Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J. Biol. Chem. 1991, 266, 4244-4250.
25. Szabo, C., Ischiropoulos, H. and Radi, R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nature Rev. Drug Discov. 2007, 6, 662-678.
26. Burdo, J., Schubert, D., and Maher, P. Glutathione production is regulated via distinct pathways in stressed and non-stressed cortical cultures. Brain Res. 2008, 1189, 12-22.
27. Griffith, O. W., and Meister, A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J. Biol. Chem. 1979, 254, 7558-7560.
28. Meister, A., and Anderson, M. E. Glutathione. Ann. Rev. Biochem. 1983, 52, 711-760.
29. Sato, H., Tamba, M., Ishii, T., and Bannai, S. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J. Biol. Chem. 1999, 274, 11455-11458.
30. Ishii, T., Itoh, K., Takahashi, S., Sato, H., Yanagawa, T., Yasutake, K., Bannai, S., and Yamamoto, M. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J. Biol. Chem. 2000, 275, 16023-16029.
31. Chan, J. Y., and Kwong, M. Impaired expression of glutathione synthetic enzyme genes in mice with targeted deletion of the Nrf2 basic-leucine zipper protein. Biochim. Biophys. Acta 2000, 1517, 19-26.
32. Hayes, J. D., Ellis, E. M., Neal, G. E., Harrison, D. J., and Manson, M. M. Cellular response to cancer chemopreventive agents: Contribution of the antioxidant responsive element to the adaptive response to oxidative and chemical stress. Biochem. Soc. Symp. 1999, 64, 141-168.
33. Nguyen, T., Sherratt, P. J., and Pickett, C. B. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu. Rev. Pharmacol. Toxicol. 2003, 43, 233-260.
34. Chen, C., and Kong, A.-N. T. Dietary chemopreventive compounds and ARE/EpRE signaling. Free Rad. Biol. Med. 2004, 36, 1505-1516.
35. Kensler, T. W., Wakabayashi, N., and Biswal, S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 2007, 47, 89-116.
36. Maher, P. A comparison of the neurotrophic activities of the flavonoid fisetin and some of its derivatives. Free Rad. Res. 2006, 40, 1105-1111.
37. Maher, P., and Hanneken, A. Flavonoids protect retinal ganglion cells from oxidative stress-induced death. Invest. Ophthalmol. Vis. Sci. 2005, 46, 4796-4803.
38. Valerio, L. G., Kepa, J. K., Pickwell, G. V., and Quattrochi, L. C. Induction of human NAD(P)H:quinone oxidoreductase (NQO1) gene expression by the flavonol quercetin. Toxicol. Lett. 2001, 119, 49-57.
39. Myhrstad, M. C. W., Carlsen, H., Nordstrom, O., Blomhoff, R., and Moskaug, J. O. Flavonoids increase the intracellular glutathione level by transactivation of the γ-glutamylcysteine synthetase catalytical subunit promoter. Free Rad. Biol. Med. 2002, 32, 386-393.
40. Hou, D.-X., Fukuda, M., Johnson, J. A., Miyamori, K., Ushikai, M., and Fujii, M. Fisetin induces transcription of NADPH:quinone oxidoreductase gene through an antioxidant responsive element-involved activation. Int. J. Oncol. 2001, 18, 1175-1179.
41. Chen, T. J., Jeng, J. Y., Lin, C. W., Wu, C. Y., and Chen, Y. C. Quercetin inhibition of ROS-dependent and -independent apoptosis in rat glioma C6 cells. Toxicol. 2006, 223, 113-126.
42. Price, R. D., Milne, S. A., Sharkey, J., and Matsuoka, N. Advances in small molecules promoting neurotrophic function. Pharmacol. Ther. 2007, 115, 292-306.
43. Chen, S., Le, W. Neuroprotective therapy in Parkinson disease. Amer. J. Ther. 2006, 13, 445-457.
44. Levy, Y. S., Gilgun-Sherki, Y., and Melamed, E., Offen, D. Therapeutic potential of neurotrophic factors in neurodegenerative diseases. BioDrugs 2005, 19, 97-127.
45. Zuccato, C., and Cattaneo, E. Role of brain-derived neurotrophic factor in Huntington’s disease. Prog. Neurobiol. 2007, 81, 294-330.
46. Keegan, K., and Halegoua, S. Signal transduction pathways in neuronal differentiation. Curr. Opin. Neurobiol. 1993, 3, 14-19.
47. Sagara, Y., Vahnnasy, J., and Maher, P. Induction of PC12 cell differentiation by flavonoids is dependent upon extracellular signal-regulated kinase activation. J. Neurochem. 2004, 90, 1144-1155.
48. Mayr, B., and Montminy, M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nature Rev. Mol. Cell Biol. 2001, 2, 599-609.
49. Carlezon, W. A., Duman, R. S., and Nestler, E. J. The many faces of CREB. Trends Neurosci. 2005, 28, 436-445.
50. Tully, T., Bourtchouladze, R., Scott, R., and Tallman, J. Targeting the CREB pathway for memory enhancers. Nat. Rev. Drug Discov. 2003, 2, 267-277.
51. Johannessen, M., Delghandi, M. P., and Moens, U. What turns CREB on? Cell. Signal. 2004, 16, 1211-1227.
52. Maher, P., Akaishi, T., and Abe, K. The flavonoid fisetin promotes ERK-dependent long-term potentiation and enhances memory. Proc. Natl. Acad. Sci. U S A 2006, 103, 16568-16573.
53. Bliss, T. V. P., and Collingridge, G. L. A synaptic model of memory: Long-term potentiation in the hippocampus. Nature 1993, 361, 31-39.
54. Barad, M., Bourtchouladze, R., Winder, D. G., Golan, H., and Kandel, E. Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc. Natl. Acad. Sci. U S A 1998, 95, 15020-15025.
55. Bevins, R. A., and Besheer, J. Object recognition in rats and mice: A non-trial non-matching-to-sample learning task to study “recognition memory.” Nature Protocols 2006, 1, 1306-1311.
56. Maher, P. The flavonoid fisetin promotes nerve cell survival from trophic factor withdrawal by enhancement of proteasome activity. Arch. Biochem. Biophys. 2008, 476(2), 139-144.
57. Abe, K., Takayanagi, M., and Saito, H. Effects of recombinant human basic fibroblast growth factor and its modified protein CS23 on survival of primary cultured neurons from various regions of fetal rat brain. Japan J. Pharmacol. 1990, 53, 221-227.
58. Kwak, M.-K., Wakabayashi, N., Itoh, K., Motohashi, H., Yamamoto, M., and Kensler, T. W. Modulation of gene expression by cancer chemopreventative dithiolethiones through the Keap1-Nrf2 pathway. J. Biol. Chem. 2003, 278, 8135-8145.
59. Kwak, M.-K., Wakabayashi, N., Greenlaw, J. L., Yamamoto, M., and Kensler, T. W. Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway. Mol. Cell. Biol. 2003, 23, 8786-9794.
60. Kwak, M.-K., and Kensler, T. W. Induction of 26S proteasome subunit PSMB5 by the bifunctional inducer 3-methylcholanthrene through the Nrf2-ARE, but not the AhR/Arnt-XRE, pathway. Biochem. Biophys. Res. Commun. 2006, 345, 1350-1357.
61. Kwak, M.-K., Huang, B., Chang, H., Kim, J.-A., and Kensler, T. W. Tissue specific increase of the catalytic subunits of the 26S proteasome by indirect antioxidant dithiolethione in mice: Enhanced activity for degradation of abnormal protein. Life Sci. 2007, 80, 2411-2420.
62. Ciechanover, A. Proteolysis: From the lysosome to ubiquitin and the proteasome. Nature Rev. Mol. Cell Biol. 2005, 6, 79-86.
63. Kisselev, A. F., and Goldberg, A. L. Proteasome inhibitors: From research tools to drug candidates. Chem. Biol. 2001, 8, 739-758.
64. Giasson, B. I., Bruening, W., Durham, H. D., and Mushynski, W. E. Activation of stress-activated protein kinases correlates with neurite outgrowth induced by protease inhibition in PC12 cells. J. Neurochem. 1999, 72, 1081-1087.
65. Obin, M., Mesco, E., Gong, X., Haas, A. L., Joseph, J., and Taylor, A. Neurite outgrowth in PC12 cells. J. Biol. Chem. 1999, 274, 11789-11795.
66. Laser, H., Mack, T. G. A., Wagner, D., and Coleman, M. P. Proteasome inhibition arrests neurite outgrowth and causes “dying-back” degeneration in primary culture. J. Neurosci. Res. 2003, 74, 906-916.
67. Klimaschewski, L., Hausott, B., Ingorokva, S., and Pfaller, K. Constitutively expressed catalytic proteasomal subunits are up-regulated during neuronal differentiation and required for axon initiation, elongation and maintenance. J. Neurochem. 2006, 96, 1708-1717.
68. Yi, J. J., and Ehlers, M. D. Emerging roles for ubiquitin and protein degradation in neuronal function. Pharmacol. Rev. 2007, 59, 14-39.
69. Chung, K. K. K., Dawson, V. L., and Dawson, T. M. The role of the ubiquitin-proteasomal pathway in Parkinson’s disease and other neurodegenerative disorders. Trends Neurosci. 2001, 24, S7-S14.
70. Ciechanover, A., and Brundin, P. The ubiquitin proteasome system in neurodegenerative diseases:Sometimes the chicken, sometimes the egg. Neuron 2003, 40, 427-446.
71. Betarbet, R., Sherer, T. B., and Greenamyre, J. T. Ubiquitin-proteasome system and Parkinson’s disease. Exper. Neurol. 2005, 191, S17-S27.
72. Kim, H., Park, B.-S., Lee, K.-G., Choi, C. Y., Jang, S. S., Kim, Y.-H., and Lee, S.-E. Effects of naturally occurring compounds on fibril formation and oxidative stress of β-amyloid. J. Agric. Food. Chem. 2005, 53, 8537-8541.
73. Wang, L., Tu, Y.-C., Lian, T.-W., Hung, J.-T., Yen, J.-H., and Wu, M.-J. Distinctive antioxidant and antiinflammatory effects of flavonols. J. Agric. Food Chem. 2006, 54, 9798-9804.
74. Sung, B., Pandey, M. K., and Aggarwal, B. B. Fisetin, an inhibitor of cyclin-dependent kinase 6, downregulates nuclear factor-kB-regulated cell proliferation, antiapoptotic and metastatic gene products through the suppression of TAK-1 and receptor-interacting protein-regulated IkBa kinase activation. Mol. Pharmacol. 2007, 71, 1703-1714.
75. Yamamoto, Y., and Gaynor, R. B. IκB kinases: Key regulators of the NF-κB pathway. Trends Biochem. Sci. 2004, 29, 72-79.
76. Bubici, C., Papa, S., Dean, K., and Franzoso, G. Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: Molecular basis and biological significance. Oncogene 2006, 25, 6731-6748.
77. Hendriks, J. J. A., de Vries, H. E., van der Pol, S. M. A., van den Berg, T. K., van Tol, E. A. F., and Dijkstra, C. D. Flavonoids inhibit myelin phagocytosis by macrophages, a structure-activity relationship study. Biochem. Pharmacol. 2003, 65, 877-885.
78. Rock, R. B., and Peterson, P. K. Microglia as a pharmacological target in infectious and inflammatory diseases on the brain. J. Neuroimmune Pharmacol. 2006, 1, 117-126.
79. Garden, G. A., and Moller, T. Microglia biology in health and disease. J. Neuroimmune Pharmacol. 2006, 1, 127-137.
80. Dringen, R. Oxidative and antioxidative potential of brain microglial cells. Antioxid. Redox Signal. 2005, 7, 1223-1233.
81. Zheng, L. T., Ock, J., Kwon, B.-M., and Suk, K. Suppressive effects of flavonoid fisetin on lipopolysaccharideinduced microglial activation and neurotoxicity. Int. Immunopharmacol. 2008, 8, 484-494.
82. van Acker, S. A. B. E., van den Berg, D.-J., Tromp, M. N. J. L., Griffioen, D. H., van Bennekom, W. P., van der Vijgh, W. J. F., and Bast, A. Structural aspects of antioxidant activity of flavonoids. Free Radic. Biol. Med. 1996, 20, 331-342.
83. Kauppinen, T. M. Multiple roles for poly(ADP-ribose)polymerase-1 in neurological disease. Neurochem. Int. 2007, 50, 954-958.
84. Geraets, L., Moonen, H. J. J., Brauers, K., Wouters, E. F. M., Bast, A., and Hageman, G. J. Dietary flavones and flavonoles are inhibitors of poly(ADP-ribose)polymerase-1 in pulmonary epithelial cells. J. Nutr. 2007, 137, 2190-2195.
85. Phillis, J. W., Horrocks, L. A., and Farooqui, A. A. Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: Their role and involvement in neurological disorders. Brain Res. Rev. 2006, 52, 201-243.
86. Li, Y., Maher, P., and Schubert, D. A role of 12-lipoxygenase in nerve cell death caused by glutathione depletion. Neuron 1997, 19, 453-463.
87. Canals, S., Casarejos, M. J., de Bernardo, S., Rodriguez-Martin, E., and Mena, M. A. Nitric oxide triggers the toxicity due to glutathione depletion in midbrain cultures through 12-lipoxygenase. J. Biol. Chem. 2003, 278, 21542-21549.
88. Kramer, B. C., Yabut, J. A., Cheong, J., Jnobaptiste, R., Robakis, T., and Olanow, C. W., Mytilineou, C. Toxicity of glutathione depletion in mesencephalic cultures: A role for arachidonic acid and its lipoxygenase metabolites. Eur. J. Neurosci. 2004, 19, 280-286.
89. Wang, H., Li, J., Follett, P. L., Zhang, Y., Cotanche, D. A., Jensen, F. E., Volpe, J. J., and Rosenberg, P. A. 12-Lipoxygenase plays a key role in cell death caused by glutathione depletion and arachidonic acid in rat oligodendrocytes. Eur. J. Neurosci. 2004, 20, 2049-2058.
90. Pratico, D., Zhukareva, V., Yao, Y., Uryu, K., Funk, C. D., Lawson, J. A., Trojanowski, J. Q., and Lee, V. M.-Y. 12/15-Lipoxygenase is increased in Alzheimer’s disease. Am. J. Pathol. 2004, 164, 1655-1662.
91. Lebeau, A., Terro, F., Rostene, W., and Pelaprat, D. Blockade of 12-lipoxygenase expression protects cortical neurons from apoptosis induced by beta-amyloid peptide. Cell Death Differ. 2004, 11, 875-884.
92. Lapchak, P. A., Maher, P., Schubert, D., and Zivin, J. A. Baicalein, an antioxidant 12/15-lipoxygenase inhibitor improves clinical rating scores following multiple infarct embolic strokes. Neuroscience 2007, 150, 585-591.
93. Firuzi, O., Zhuo, J., Chinnici, C. M., Wisniewski, T., and Pratico, D. 5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer’s disease. FASEB J. 2008, 22, 1169-1178.
94. Hsieh, R. J., German, J. B., and Kinsella, J. E. Relative inhibitory potencies of flavonoids on 12-lipoxygenase of fish gill. Lipids 1988, 23, 322-326.
95. Laughton, M. J., Evans, P. J., and Moroney, M. A., Hoult, J. R. S., Halliwell, B. Inhibition of mammalian 5-lipoxygenase and cyclo-oxygenase by flavonoids and phenolic dietary additives. Biochem. Pharmacol. 1991, 42, 1673-1681.
96. Sadik, C. D., Sies, H., and Schewe, T. Inhibition of 15-lipoxygenases by flavonoids: Structure-activity relations and mode of action. Biochem. Pharmacol. 2003, 65, 773-781.
97. Knockaert, M., Greengard, P., and Meijer, L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 2002, 23, 417-425.
98. Lu, H., Chang, D. J., Baratte, B., Meijer, L., and Schulze-Gahmen, U. Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin. J. Med. Chem. 2005, 48, 737-743.
99. Sun, G. Y., Horrocks, L. A., and Farooqui, A. A. The roles of NADPH oxidase and phospholipases A2 in oxidative and inflammatory responses in neurodegenerative diseases. J. Neurochem. 2007, 103, 1-16.
100. Steffen, Y., Gruber, C., Schewe, T., and Sies, H. Mono-O-methylated flavonols and other flavonoids as inhibitors of endothelial NADPH oxidase. Arch. Biochem. Biophys. 2008, 469, 209-219.
101. De Santi, C., Pietrabissa, A., Mosca, F., and Pacifici, G. M. Methylation of quercetin and fisetin, flavonoids widely distributed in edible vegetables, fruits and wine, by human liver. Int. J. Clin. Pharmacol. Ther. 2002, 40, 207-212.
102. Grubisha, O., Smith, B. C., and Denu, J. M. Small molecule regulation of Sir2 protein deacetylases. FEBS J. 2005, 272, 4607-4616.
103. Anekonda, T. S., Reddy, P. H. Neuronal protection by sirtuins in Alzheimer’s disease. J. Neurochem. 2006, 96, 305-313.
104. Kim, D., Nguyen, M. D., Dobbin, M. M., Fischer, A., Sanabenesi, F., Rodgers, J. T., Delalle, I., Baur, J. A., Sui, G., Armour, S. M., Puigserver, P., Sinclair, D. A., and Tsai, L. H. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer’s disease and amyotrophic lateral sclerosis. EMBO J. 2007, 26, 3169-3179.
105. Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L.-L., Scherer, B., and Sinclair, D. A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425, 191-196.
106. Kaeberlein, M., McDonagh, T., Heltweg, B., Hixon, J., Westman, E. A., Caldwell, S. D., Napper, A., Curtis, R., DiStefano, P. S., Fields, S., Bedalov, A., and Kennedy, B. K. Substrate-specific activation of sirtuins by resveratrol. J. Biol. Chem. 2005, 280, 17038-17045.
107. Garber, K. A mid-life crisis for aging theory. Nature Biotechnol. 2008, 26, 371-374.
108. Manach, C., Williamson, G., Morand, C., Scalbert, A., and Remesy, C. Bioavailability and bioefficacy of polyphenols in humans: I. Review of 97 bioavailability studies. Am. J. Clin. Nutr. 2005, 81, 230S-242S.
109. Nielsen, S. E., Breinholt, V., Justesen, U., Cornett, C., and Dragsted, L. O. In vitro biotransformation of flavonoids by rat liver microsomes. Xenobiotica 1998, 28, 389-401.
110. Watjen, W., Michels, G., Steffan, B., Niering, P., Chovolou, Y., Kampkotter, A., Tan-Thi, Q.-H., Proksch, P., and Kahl, R. Low concentrations of flavonoids are protective in rat H4IIE cells whereas high concentrations cause DNA damage and apoptosis. J. Nutr. 2005, 135, 525-531.
111. Carter, G. W., Young, P. R., Albert, D. H., Bouska, J., Dyer, R., Bell, R. L., Summers, J. B., and Brooks, D. W. 5-Lipoxygenase inhibitory activity of zileuton. J. Pharmacol. Exp. Ther. 1991, 256, 929-937.
112. Sekiya, K., and Okuda, H. Selective inhibition of platelet lipoxygenase by baicalein. Biochem. Biophys. Res. Commun. 1982, 105, 1090-1095.
113. Auerbach, B. J., Kiely, J. S., and Conrnicell, J. A. A spectrophotometric microtiter-based assay for the detection of hydroperoxy derivatives of linoleic acid. Anal. Biochem. 1992, 201, 375-380.
114. Balch, W. E., Morimoto, R. I., Dillin, A., and Kelly, J. W. Adapting proteostasis for disease intervention. Science 2008, 319, 916-919.